Recently, Junshi Biosciences announced it has received approval from the National Association of Financial Market Institutional Investors (NAFMII) to register and issue medium-term notes (MTNs) with a total amount of up to RMB 2 billion. This approval marks a significant step in the company’s strategy to diversify its financing channels, helping optimize its debt structure, reduce funding costs, and provide stable capital support for ongoing R&D investments and commercial expansion.Medium-term notes are mid-to-long-term debt instruments issued in China’s interbank bond market, typically with maturities ranging from one to five years. They offer advantages such as flexible terms and substantial financing capacity. As a biopharmaceutical company focused on innovative drug development, Junshi has made notable progress in areas including oncology immunotherapy, autoimmune diseases, and anti-infective therapies, with several core products already in commercialization. However, given the long timelines and high costs associated with drug development, sustained capital is essential. Issuing MTNs allows the company to secure low-cost funding without diluting equity, thereby strengthening its financial resilience.The approved RMB 2 billion MTN quota not only reflects recognition from regulators and capital markets of Junshi’s creditworthiness and growth outlook but also demonstrates the company’s growing sophistication in capital management. Going forward, Junshi is well-positioned to leverage this financing tool to accelerate global clinical development, expand manufacturing capacity, and enhance its market presence—solidifying its competitive edge in the biopharmaceutical sector both in China and worldwide.
近日，君实生物宣布已获中国银行间市场交易商协会批准，注册发行总额不超过20亿元人民币的中期票据。此次获批标志着公司在多元化融资渠道方面迈出关键一步，有助于优化其债务结构、降低融资成本，并为持续的研发投入和商业化拓展提供稳定资金支持。中期票据是一种在银行间债券市场发行的中长期债务融资工具，通常期限为1至5年，具有灵活性高、融资规模大等优势。作为一家专注于创新药研发的生物制药企业，君实生物近年来在肿瘤免疫、自身免疫性疾病及抗感染等领域取得显著进展，多款核心产品已进入商业化阶段。然而，新药研发周期长、投入大，对资金需求持续旺盛。通过发行中期票据，公司可在不稀释股权的前提下获取低成本资金，增强财务稳健性。此次20亿元中期票据的注册额度，不仅体现了监管机构和资本市场对公司信用资质与经营前景的认可，也反映出君实生物在资本运作方面的成熟度不断提升。未来，公司有望借助这一融资工具进一步加速全球临床开发、产能建设及市场布局，巩固其在中国乃至全球生物医药领域的竞争力。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/6796.html